Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon May 23, 2023 10:57am
149 Views
Post# 35460195

RE:Please go to 10$ USD

RE:Please go to 10$ USD

The $10ps, is certainly not out of line. Like most things in life......takes time.
from its present day $2.45-$2.50 , things need to settle after that 20% run up over last few days.
By the close of market, Thursday there will be a N.R. Discussing the abstract details. Made public 5 pm at ASCO.
Assuming, being well received, price should be well above $3CDN , something we have not seen in a long time.
Then , it becomes a matter of " what next"?

The KOL discussion early June is being well promoted.
The pancreatic and/ or CAR-t , information; again if good will give a great platform to continue the upward trend.
just know, there are many who bought within the last few months that are up 50% or more.
Many of which could care less what Onc is or does. 

point?
There will be selling pressures along the way, Until a phase 3 partnership is announced, then " whole new ball game".
All analysts covering & Onc management indicate " phase 3 guidance,  second half of this year".
They can not do phase 3 on their own. So, that announcement needs to be within next 6 months.
it has been said many times, for many years " this is the year".
For a multitude of reasons, this must be the year.
conclusion?
We have some very short term stuff, within next few days.
and
medium term opportunities, which we can only vision after the short term data is out.
 

<< Previous
Bullboard Posts
Next >>